1
|
Wong G, Bienes KM, Xiii A, Fausther-Bovendo H, Kobinger GP. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp. Antiviral Res 2024; 226:105873. [PMID: 38580170 DOI: 10.1016/j.antiviral.2024.105873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 03/22/2024] [Accepted: 03/25/2024] [Indexed: 04/07/2024]
Abstract
In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013-2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013-2016 outbreak and advancing to randomized controlled trials into the 2018-2020 African outbreak. We end with a brief discussion of the hurdles and promise toward mAb therapeutic use against infectious disease.
Collapse
Affiliation(s)
- Gary Wong
- Virology Unit, Institut Pasteur Du Cambodge, Pasteur Network, Phnom Penh, Cambodia
| | - Kathrina Mae Bienes
- Virology Unit, Institut Pasteur Du Cambodge, Pasteur Network, Phnom Penh, Cambodia
| | - Ara Xiii
- Department of Immunology and Microbiology, The Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
| | - Hugues Fausther-Bovendo
- Department of Immunology and Microbiology, The Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA
| | - Gary P Kobinger
- Department of Immunology and Microbiology, The Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA
| |
Collapse
|
2
|
Berger A, Pedersen J, Kowatsch MM, Scholte F, Lafrance MA, Azizi H, Li Y, Gomez A, Wade M, Fausther-Bovendo H, de La Vega MA, Jelinski J, Babuadze G, Nepveu-Traversy ME, Lamarre C, Racine T, Kang CY, Gaillet B, Garnier A, Gilbert R, Kamen A, Yao XJ, Fowke KR, Arts E, Kobinger G. Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques. Vaccines (Basel) 2024; 12:369. [PMID: 38675751 PMCID: PMC11053682 DOI: 10.3390/vaccines12040369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/25/2024] [Accepted: 03/26/2024] [Indexed: 04/28/2024] Open
Abstract
Currently, no effective vaccine to prevent human immunodeficiency virus (HIV) infection is available, and various platforms are being examined. The vesicular stomatitis virus (VSV) vaccine vehicle can induce robust humoral and cell-mediated immune responses, making it a suitable candidate for the development of an HIV vaccine. Here, we analyze the protective immunological impacts of recombinant VSV vaccine vectors that express chimeric HIV Envelope proteins (Env) in rhesus macaques. To improve the immunogenicity of these VSV-HIV Env vaccine candidates, we generated chimeric Envs containing the transmembrane and cytoplasmic tail of the simian immunodeficiency virus (SIV), which increases surface Env on the particle. Additionally, the Ebola virus glycoprotein was added to the VSV-HIV vaccine particles to divert tropism from CD4 T cells and enhance their replications both in vitro and in vivo. Animals were boosted with DNA constructs that encoded matching antigens. Vaccinated animals developed non-neutralizing antibody responses against both the HIV Env and the Ebola virus glycoprotein (EBOV GP) as well as systemic memory T-cell activation. However, these responses were not associated with observable protection against simian-HIV (SHIV) infection following repeated high-dose intra-rectal SHIV SF162p3 challenges.
Collapse
Affiliation(s)
- Alice Berger
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Jannie Pedersen
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Monika M. Kowatsch
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; (M.M.K.); (K.R.F.)
| | - Florine Scholte
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Marc-Alexandre Lafrance
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Hiva Azizi
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Yue Li
- Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada; (Y.L.); (C.-Y.K.); (E.A.)
| | - Alejandro Gomez
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Matthew Wade
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Hugues Fausther-Bovendo
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Marc-Antoine de La Vega
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Joseph Jelinski
- Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA;
| | - George Babuadze
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | | | - Claude Lamarre
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Unversité Laval, Quebec, QC G1V 0A6, Canada; (A.B.); (J.P.); (F.S.); (M.-A.L.); (H.A.); (A.G.); (M.W.); (H.F.-B.); (M.-A.d.L.V.); (G.B.); (C.L.)
| | - Trina Racine
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC G1E 6W2, Canada; (T.R.); (X.-J.Y.)
| | - Chil-Yong Kang
- Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada; (Y.L.); (C.-Y.K.); (E.A.)
| | - Bruno Gaillet
- Department of Chemical Engineering, Faculty of Science and Engineering, Laval University, Quebec, QC G1V 0A6, Canada; (B.G.); (A.G.)
| | - Alain Garnier
- Department of Chemical Engineering, Faculty of Science and Engineering, Laval University, Quebec, QC G1V 0A6, Canada; (B.G.); (A.G.)
| | - Rénald Gilbert
- Department of Production Platforms and Analytics, Human Health Therapeutics Research Center, National Research Council, Montreal, QC H4P 2R2, Canada;
| | - Amine Kamen
- Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada;
| | - Xiao-Jian Yao
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC G1E 6W2, Canada; (T.R.); (X.-J.Y.)
| | - Keith R. Fowke
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; (M.M.K.); (K.R.F.)
| | - Eric Arts
- Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada; (Y.L.); (C.-Y.K.); (E.A.)
| | - Gary Kobinger
- Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA;
| |
Collapse
|
3
|
Nepveu-Traversy ME, Fausther-Bovendo H, Babuadze G(G. Human Tick-Borne Diseases and Advances in Anti-Tick Vaccine Approaches: A Comprehensive Review. Vaccines (Basel) 2024; 12:141. [PMID: 38400125 PMCID: PMC10891567 DOI: 10.3390/vaccines12020141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2023] [Revised: 01/18/2024] [Accepted: 01/23/2024] [Indexed: 02/25/2024] Open
Abstract
This comprehensive review explores the field of anti-tick vaccines, addressing their significance in combating tick-borne diseases of public health concern. The main objectives are to provide a brief epidemiology of diseases affecting humans and a thorough understanding of tick biology, traditional tick control methods, the development and mechanisms of anti-tick vaccines, their efficacy in field applications, associated challenges, and future prospects. Tick-borne diseases (TBDs) pose a significant and escalating threat to global health and the livestock industries due to the widespread distribution of ticks and the multitude of pathogens they transmit. Traditional tick control methods, such as acaricides and repellents, have limitations, including environmental concerns and the emergence of tick resistance. Anti-tick vaccines offer a promising alternative by targeting specific tick proteins crucial for feeding and pathogen transmission. Developing vaccines with antigens based on these essential proteins is likely to disrupt these processes. Indeed, anti-tick vaccines have shown efficacy in laboratory and field trials successfully implemented in livestock, reducing the prevalence of TBDs. However, some challenges still remain, including vaccine efficacy on different hosts, polymorphisms in ticks of the same species, and the economic considerations of adopting large-scale vaccine strategies. Emerging technologies and approaches hold promise for improving anti-tick vaccine development and expanding their impact on public health and agriculture.
Collapse
Affiliation(s)
| | - Hugues Fausther-Bovendo
- Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 75550, USA;
| | - George (Giorgi) Babuadze
- Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 75550, USA;
| |
Collapse
|
4
|
de La Vega MA, Polychronopoulou E, XIII A, Ding Z, Chen T, Liu Q, Lan J, Nepveu-Traversy ME, Fausther-Bovendo H, Zaidan MF, Wong G, Sharma G, Kobinger GP. SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants. Emerg Microbes Infect 2023; 12:e2169198. [PMID: 36655944 PMCID: PMC9980403 DOI: 10.1080/22221751.2023.2169198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
During a pandemic, effective vaccines are typically in short supply, particularly at onset intervals when the wave is accelerating. We conducted an observational, retrospective analysis of aggregated data from all patients who tested positive for SARS-CoV-2 during the waves caused by the Delta and Omicron variants, stratified based on their known previous infection and vaccination status, throughout the University of Texas Medical Branch (UTMB) network. Next, the immunity statuses within each medical parameter were compared to naïve individuals for the effective decrease of occurrence. Lastly, we conducted studies using mice and pre-pandemic human samples for IgG responses to viral nucleocapsid compared to spike protein toward showing a functional component supportive of the medical data results in relation to the immunity types. During the Delta and Omicron waves, both infection-induced and hybrid immunities were associated with a trend of equal or greater decrease of occurrence than vaccine-induced immunity in hospitalizations, intensive care unit admissions, and deaths in comparison to those without pre-existing immunity, with hybrid immunity often trending with the greatest decrease. Compared to individuals without pre-existing immunity, those vaccinated against SARS-CoV-2 had a significantly reduced incidence of COVID-19, as well as all subsequent medical parameters. Though vaccination best reduces health risks associated with initial infection toward acquiring immunity, our findings suggest infection-induced immunity is as or more effective than vaccination in reducing the severity of reinfection from the Delta or Omicron variants, which should inform public health response at pandemic onset, particularly when triaging towards the allotment of in-demand vaccinations.
Collapse
Affiliation(s)
- Marc-Antoine de La Vega
- Galveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA
| | | | - Ara XIII
- Galveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA
| | - Zhe Ding
- Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of China,University of Chinese Academy of Sciences, Beijing, People’s Republic of China
| | - Tong Chen
- Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of China,University of Chinese Academy of Sciences, Beijing, People’s Republic of China
| | - Qixing Liu
- Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of China,University of Chinese Academy of Sciences, Beijing, People’s Republic of China
| | - Jiaming Lan
- Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of China
| | | | | | - Mohammed F. Zaidan
- Department of Internal Medicine, Division of Pulmonary, Critical Care, & Sleep Medicine, University of Texas Medical Branch, Galveston, TX, USA
| | - Gary Wong
- Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of China
| | - Gulshan Sharma
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
| | - Gary P. Kobinger
- Galveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA, Gary P. Kobinger Galveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, 301 University Blvd, Galveston, TX77555, USA
| |
Collapse
|
5
|
Jelinski J, Kowatsch MM, Lafrance MA, Berger A, Pedersen J, Azizi H, Li Y, Scholte F, Gomez A, Hollett N, Le T, Wade M, Fausther-Bovendo H, de La Vega MA, Babuadze G, XIII A, Lamarre C, Racine T, Kang CY, Yao XJ, Alter G, Arts E, Fowke KR, Kobinger GP. Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen. Emerg Microbes Infect 2023; 12:2251595. [PMID: 37649434 PMCID: PMC10486302 DOI: 10.1080/22221751.2023.2251595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Revised: 08/02/2023] [Accepted: 08/20/2023] [Indexed: 09/01/2023]
Abstract
Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.
Collapse
Affiliation(s)
- Joseph Jelinski
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| | - Monika M. Kowatsch
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | | | - Alice Berger
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada
| | - Jannie Pedersen
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada
| | - Hiva Azizi
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada
| | - Yue Li
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada
| | - Florine Scholte
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada
| | - Alejandro Gomez
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada
| | - Natasha Hollett
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - Toby Le
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - Matthew Wade
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada
| | - Hugues Fausther-Bovendo
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| | - Marc-Antoine de La Vega
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| | - George Babuadze
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| | - Ara XIII
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| | - Claude Lamarre
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada
| | - Trina Racine
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada
| | - Chil-Yong Kang
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada
| | - Xiao-Jian Yao
- Department of Medical Microbiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
| | - Galit Alter
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
| | - Eric Arts
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada
| | - Keith R. Fowke
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - Gary P. Kobinger
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| |
Collapse
|
6
|
El Ghassem A, Apolloni A, Vial L, Bouvier R, Bernard C, Khayar MS, Cheikh Ahmed M, Fausther-Bovendo H, Beyit AD, Yahya B, Ould El Mamy MB, Elbara A, Bollahi MA, Cêtre-Sossah C, Ould Mohamed Salem Boukhary A. Risk factors associated with Crimean-Congo hemorrhagic fever virus circulation among human, livestock and ticks in Mauritania through a one health retrospective study. BMC Infect Dis 2023; 23:764. [PMID: 37932678 PMCID: PMC10626674 DOI: 10.1186/s12879-023-08779-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Accepted: 11/01/2023] [Indexed: 11/08/2023] Open
Abstract
BACKGROUND Crimean Congo hemorrhagic fever (CCHF) is endemic in Southern Mauritania where recurrent outbreaks have been constantly observed since the 1980's. The present study is the first to assess CCHFV antibodies and RNA in humans. METHODS A retrospective study was conducted using 263 humans and 1380 domestic animals serum samples, and 282 tick specimens of Hyalomma genus collected from 54 settings in 12 provinces across Mauritania. Antibodies targeting CCHF viral nucleoprotein were detected in animal and human sera using double-antigen ELISA. CCHFV specific RNA was detected in human and animal sera as well as tick supernatants using a CCHFV real time RT-PCR kit. Individual characteristics of sampled hosts were collected at the same time and data were geo-referenced. Satellite data of several environmental and climatic factors, were downloaded from publicly available datasets, and combined with data on livestock mobility, animal and human density, road accessibility and individual characteristics to identify possible risk factors for CCHFV spatial distribution. To this end, multivariate logistic models were developed for each host category (human, small and large ruminants). RESULTS The overall CCHFV antibody prevalence was 11.8% [95% CI: 8.4-16.3] in humans (17.9% in 2020 and 5.4% in 2021; p = 0.0017) and 33.1% (95% CI: 30.1-36.3) in livestock. CCHFV-specific antibodies were detected in 91 (18.1%) out of 502 sheep, 43 (9.0%) out of 477 goats, 144 (90.5%) out of 161 dromedaries and 179 (74.6%) out of 240 cattle. CCHFV RNA was detected in only 2 (0.7%) sera out of 263 animals herders samples from Hodh El Gharbi province and in 32 (11.3%) out of 282 Hyalomma ticks. In humans as well as in animals, seropositivity was not associated with sex or age groups. The multivariate analysis determined the role of different environmental, climatic and anthropic factors in the spatial distribution of the disease with animal mobility and age being identified as risk factors. CONCLUSION Results of the present study demonstrate the potential risk of CCHF for human population in Mauritania primarily those living in rural areas in close vicinity with animals. Future studies should prioritize an integrative human and veterinary approach for better understanding and managing Crimean-Congo hemorrhagic fever.
Collapse
Affiliation(s)
- Abdellahi El Ghassem
- Université de Nouakchott, UR GEMI, BP 5026, Nouakchott, Mauritania.
- ONARDEP, BP 167, Nouakchott, Mauritania.
| | - Andrea Apolloni
- CIRAD, UMR ASTRE, Montpellier Cedex, 34398, France.
- ASTRE, University of Montpellier, CIRAD, INRAe, Montpellier, France.
| | - Laurence Vial
- CIRAD, UMR ASTRE, Montpellier Cedex, 34398, France
- ASTRE, University of Montpellier, CIRAD, INRAe, Montpellier, France
| | - Romain Bouvier
- CIRAD, UMR ASTRE, Montpellier Cedex, 34398, France
- ASTRE, University of Montpellier, CIRAD, INRAe, Montpellier, France
| | - Celia Bernard
- CIRAD, UMR ASTRE, Montpellier Cedex, 34398, France
- ASTRE, University of Montpellier, CIRAD, INRAe, Montpellier, France
| | | | | | - Hugues Fausther-Bovendo
- GUARD, Batiscan, QC, G0X 1A0, Canada
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, United States
| | | | | | | | | | | | - Catherine Cêtre-Sossah
- CIRAD, UMR ASTRE, Montpellier Cedex, 34398, France
- ASTRE, University of Montpellier, CIRAD, INRAe, Montpellier, France
| | | |
Collapse
|
7
|
Pedersen J, Koumakpayi IH, Babuadze G, Baz M, Ndiaye O, Faye O, Diagne CT, Dia N, Naghibosadat M, McGeer A, Muberaka S, Moukandja IP, Ndidi S, Tauil CB, Lekana-Douki JB, Loucoubar C, Faye O, Sall A, Magalhães KG, Weis N, Kozak R, Kobinger GP, Fausther-Bovendo H. Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic. Sci Rep 2022; 12:12962. [PMID: 35902675 PMCID: PMC9333058 DOI: 10.1038/s41598-022-17241-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 07/22/2022] [Indexed: 12/22/2022] Open
Abstract
Early predictions forecasted large numbers of severe acute respiratory syndrome coronavirus (SARS-CoV-2) cases and associated deaths in Africa. To date, Africa has been relatively spared. Various hypotheses were postulated to explain the lower than anticipated impact on public health in Africa. However, the contribution of pre-existing immunity is yet to be investigated. In this study, the presence of antibodies against SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in pre-pandemic samples from Africa, Europe, South and North America was examined by ELISA. The protective efficacy of N specific antibodies isolated from Central African donors was tested by in vitro neutralization and in a mouse model of SARS-CoV-2 infection. Antibodies against SARS-CoV-2 S and N proteins were rare in all populations except in Gabon and Senegal where N specific antibodies were prevalent. However, these antibodies failed to neutralize the virus either in vitro or in vivo. Overall, this study indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemic. However, this pre-existing humoral immunity does not impact viral fitness in rodents suggesting that other human immune defense mechanisms could be involved. In Africa, seroprevalence studies using the N protein are over-estimating SARS-CoV-2 circulation.
Collapse
Affiliation(s)
- Jannie Pedersen
- Département de Microbiologie-Infectiologie et Immunologie, Université Laval, Quebec City, Canada
| | | | - Giorgi Babuadze
- Biological Sciences Platform, University of Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Mariana Baz
- Département de Microbiologie-Infectiologie et Immunologie, Université Laval, Quebec City, Canada
| | | | - Oumar Faye
- Institut Pasteur de Dakar, Dakar, Senegal
| | | | - Ndongo Dia
- Institut Pasteur de Dakar, Dakar, Senegal
| | - Maedeh Naghibosadat
- Biological Sciences Platform, University of Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Allison McGeer
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Microbiology, Sinai Health System/University Health Network, Toronto, Canada
| | - Samira Muberaka
- Biological Sciences Platform, University of Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, Canada
| | | | - Stella Ndidi
- Centre Hospitalier Universitaire de Libreville, Libreville, Gabon
| | - Carlos B Tauil
- Laboratory of Immunology and Inflammation, University of Brasilia, Brasilia, Brazil
| | - Jean-Bernard Lekana-Douki
- Unité d'Evolution Epidémiologie et Résistances Parasitaires, Centre Interdisciplinaire de Recherches Médicales de Franceville, Franceville, Gabon
| | | | | | | | - Kelly G Magalhães
- Laboratory of Immunology and Inflammation, University of Brasilia, Brasilia, Brazil
| | - Nina Weis
- Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.,Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Robert Kozak
- Biological Sciences Platform, University of Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Gary P Kobinger
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA
| | - Hugues Fausther-Bovendo
- Département de Microbiologie-Infectiologie et Immunologie, Université Laval, Quebec City, Canada. .,Global Urgent and Advanced Research and Development, 911 Rue Principale, Unit 100, Batiscan, QC, G0X 1A0, Canada.
| |
Collapse
|
8
|
Pedersen J, Moukandja IP, Ndidi S, Sørensen AL, Koumakpayi IH, Lekana-Douki JB, Vachon ML, Weis N, Kobinger G, Fausther-Bovendo H. An adaptable platform for in-house hepatitis C serology. J Virol Methods 2022; 308:114586. [PMID: 35850366 DOI: 10.1016/j.jviromet.2022.114586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 06/16/2022] [Accepted: 07/14/2022] [Indexed: 12/09/2022]
Abstract
Serology-based diagnosis remains one of the major tools for diagnosis and surveillance of infectious diseases. However, for many neglected diseases no or only few commercial assays are available and often with prices prohibiting large scale testing in low and middle-income countries (LMICs). We developed an adaptable enzyme-linked immunoassay (ELISA) using hepatitis C virus (HCV) as a proof-of-concept application. By combining the maltose-binding-protein with a multiepitope HCV protein, we were able to obtain a high concentration of protein suitable for downstream applications. Following optimization, the assay was verified using previously tested human samples from Canada, Denmark and Gabon in parallel with the use of a commercial protein. Sensitivity and specificity were calculated to 98 % and 97 % respectively, after accounting for non-specific binding and assay optimization. This study provides a thorough description of the development, and validation of a multiepitope ELISA-based diagnostic assay against HCV, which could be implemented at low cost. The described methodology can be readily adapted to develop novel ELISA-based diagnostic assays for other infectious pathogens with well-described immunogenic epitopes. This method could improve the diagnosis of neglected diseases for which affordable diagnostic assays are lacking.
Collapse
Affiliation(s)
- Jannie Pedersen
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada
| | | | - Stella Ndidi
- Centre Hospitalier Universitaire de Libreville, Libreville BP2228, Gabon
| | - Anna-Louise Sørensen
- Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Jean-Bernard Lekana-Douki
- Unité d'Evolution Epidémiologie et Résistances Parasitaires, Centre Interdisciplinaire de Recherches Médicales de Franceville, Franceville, Gabon
| | - Marie-Louise Vachon
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec G1V 4G2, Canada
| | - Nina Weis
- Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Gary Kobinger
- Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
| | - Hugues Fausther-Bovendo
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada; Global Urgent and Advanced Research and Development - GUARD, 911 Rue Principale, unit 100, Batiscan, Quebec G0X 1A0, Canada.
| |
Collapse
|
9
|
Fausther-Bovendo H, Kobinger G. The road to effective and accessible antibody therapies against Ebola virus. Curr Opin Virol 2022; 54:101210. [DOI: 10.1016/j.coviro.2022.101210] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 02/17/2022] [Accepted: 02/21/2022] [Indexed: 11/03/2022]
|
10
|
Fausther-Bovendo H, Qiu X, Babuadze GG, Azizi H, Pedersen J, Wong G, Kobinger GP. Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia. J Infect Dis 2022; 225:1852-1855. [PMID: 34791300 PMCID: PMC9113424 DOI: 10.1093/infdis/jiab552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 10/27/2021] [Indexed: 11/14/2022] Open
Abstract
Numerous studies have demonstrated the importance of the adaptive immunity for survival following Ebola virus (EBOV) infection. To evaluate the contribution of tissue damage to EBOV-induced immune suppression, acute liver damage or hemolysis, 2 symptoms associated with lethal EBOV infection, were chemically induced in vaccinated mice. Results show that either liver damage or hemolysis was sufficient to inhibit the host humoral response against EBOV glycoprotein and to drastically reduce the level of circulating T cells. This study thus provides a possible mechanism for the limited specific antibody production and lymphopenia in individuals with lethal hemorrhagic fever infections.
Collapse
Affiliation(s)
- Hugues Fausther-Bovendo
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Xiangguo Qiu
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
| | - George Giorgi Babuadze
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Hiva Azizi
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Jannie Pedersen
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Gary Wong
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
| | - Gary P Kobinger
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
- Department of Pathology and Laboratory Medicine, University of Pennsylvania School 27 of Medicine, Philadelphia, Pennsylvania, USA
| |
Collapse
|
11
|
Babuadze GG, Fausther-Bovendo H, deLaVega MA, Lillie B, Naghibosadat M, Shahhosseini N, Joyce MA, Saffran HA, Lorne Tyrrell D, Falzarano D, Senthilkumaran C, Christie-Holmes N, Ahn S, Gray-Owen SD, Banerjee A, Mubareka S, Mossman K, Dupont C, Pedersen J, Lafrance MA, Kobinger GP, Kozak R. Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. NPJ Vaccines 2022; 7:49. [PMID: 35474311 PMCID: PMC9042934 DOI: 10.1038/s41541-022-00461-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Accepted: 02/18/2022] [Indexed: 12/30/2022] Open
Abstract
The SARS-CoV-2 pandemic is an ongoing threat to global health, and wide-scale vaccination is an efficient method to reduce morbidity and mortality. We designed and evaluated two DNA plasmid vaccines, based on the pIDV-II system, expressing the SARS-CoV-2 spike gene, with or without an immunogenic peptide, in mice, and in a Syrian hamster model of infection. Both vaccines demonstrated robust immunogenicity in BALB/c and C57BL/6 mice. Additionally, the shedding of infectious virus and the viral burden in the lungs was reduced in immunized hamsters. Moreover, high-titers of neutralizing antibodies with activity against multiple SARS-CoV-2 variants were generated in immunized animals. Vaccination also protected animals from weight loss during infection. Additionally, both vaccines were effective at reducing both pulmonary and extrapulmonary pathology in vaccinated animals. These data show the potential of a DNA vaccine for SARS-CoV-2 and suggest further investigation in large animal and human studies could be pursued.
Collapse
Affiliation(s)
- George Giorgi Babuadze
- grid.17063.330000 0001 2157 2938Biological Sciences Platform, University Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Ontario, ON Canada
| | - Hugues Fausther-Bovendo
- grid.23856.3a0000 0004 1936 8390Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, QC Canada
| | - Marc-Antoine deLaVega
- grid.23856.3a0000 0004 1936 8390Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, QC Canada
| | - Brandon Lillie
- grid.34429.380000 0004 1936 8198Ontario Veterinary College, University of Guelph, Guelph, ON Canada
| | - Maedeh Naghibosadat
- grid.17063.330000 0001 2157 2938Biological Sciences Platform, University Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Ontario, ON Canada
| | - Nariman Shahhosseini
- grid.23856.3a0000 0004 1936 8390Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, QC Canada
| | - Michael A. Joyce
- grid.17089.370000 0001 2190 316XDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB Canada ,grid.17089.370000 0001 2190 316XLi Ka Shing Institute of Virology, University of Alberta, Edmonton, AB Canada
| | - Holly A. Saffran
- grid.17089.370000 0001 2190 316XDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB Canada ,grid.17089.370000 0001 2190 316XLi Ka Shing Institute of Virology, University of Alberta, Edmonton, AB Canada
| | - D. Lorne Tyrrell
- grid.17089.370000 0001 2190 316XDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB Canada ,grid.17089.370000 0001 2190 316XLi Ka Shing Institute of Virology, University of Alberta, Edmonton, AB Canada
| | - Darryl Falzarano
- grid.25152.310000 0001 2154 235XVaccine and Infectious Disease Organization, Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK Canada
| | - Chandrika Senthilkumaran
- grid.17063.330000 0001 2157 2938Biological Sciences Platform, University Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Ontario, ON Canada
| | - Natasha Christie-Holmes
- grid.17063.330000 0001 2157 2938Combined Containment Level 3 Unit, Temerty Faculty of Medicine, University of Toronto, Toronto, ON Canada
| | - Steven Ahn
- grid.17063.330000 0001 2157 2938Department of Molecular Genetics, University of Toronto, Toronto, ON Canada
| | - Scott D. Gray-Owen
- grid.17063.330000 0001 2157 2938Department of Molecular Genetics, University of Toronto, Toronto, ON Canada
| | - Arinjay Banerjee
- grid.25152.310000 0001 2154 235XVaccine and Infectious Disease Organization, Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK Canada
| | - Samira Mubareka
- grid.17063.330000 0001 2157 2938Biological Sciences Platform, University Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Ontario, ON Canada ,grid.413104.30000 0000 9743 1587Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON Canada ,grid.17063.330000 0001 2157 2938Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
| | - Karen Mossman
- grid.25073.330000 0004 1936 8227Department of Medicine, McMaster University, Hamilton, ON Canada
| | - Chanel Dupont
- grid.17063.330000 0001 2157 2938Biological Sciences Platform, University Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Ontario, ON Canada
| | - Jannie Pedersen
- grid.23856.3a0000 0004 1936 8390Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, QC Canada
| | - Mark-Alexandre Lafrance
- grid.23856.3a0000 0004 1936 8390Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, QC Canada
| | - Gary P. Kobinger
- grid.23856.3a0000 0004 1936 8390Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, QC Canada ,grid.21613.370000 0004 1936 9609Department of Medical Microbiology, University of Manitoba, Winnipeg, MB Canada ,grid.25879.310000 0004 1936 8972Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA USA
| | - Robert Kozak
- grid.17063.330000 0001 2157 2938Biological Sciences Platform, University Toronto, Sunnybrook Research Institute at Sunnybrook Health Sciences Centre, Ontario, ON Canada ,grid.413104.30000 0000 9743 1587Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON Canada ,grid.17063.330000 0001 2157 2938Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
| |
Collapse
|
12
|
Babuadze GG, Echanove J, Lamarre C, deLaVega MA, Fausther-Bovendo H, Racine T, M Gomez A, Azizi H, Wade M, Kozak R, Kobinger GP. A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. Vaccine 2021; 39:7175-7181. [PMID: 34774358 DOI: 10.1016/j.vaccine.2021.10.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 07/01/2021] [Accepted: 10/06/2021] [Indexed: 11/17/2022]
Abstract
The development of new, low-cost vaccines and effective gene therapies requires accurate delivery and high-level expression of candidate genes. We developed a plasmid vector, pIDV-II, that allows for both easy manipulation and high expression of exogenous genes in mammalian cells. This plasmid is based upon the pVax1 plasmid and shares a common structure with typical mammalian transcription units. It is composed of a chicken β-actin promoter (CAG), followed by an intron and flanked by two restriction sites, and also includes a post-transcriptional regulatory element, followed by a transcriptional termination signal. While the modification of pVax1 elements either decreased eGFP expression levels or had no effect at all, replacement of the promoter, the poly-A signal, deletion of the T7 and AmpR promoters, and inversion of the ORI-Neo/Kan cassette, significantly increased in vitro eGFP expression with the modified plasmid called pIDV-II. To further evaluate our vector, expression levels of three viral antigens were compared in cell lines transfected either with pVax1 or pCAGGS backbones as controls. Higher transgene expression was consistently observed with pIDV-II. The humoral and cellular responses generated in mice immunized with pIDV-II vs pVax1 expressing each viral antigen individually were superior by 2-fold or more as measured by ELISA and ELISPOT assays. Overall these results indicate that pIDV-II induces robust transgene expression, with concomitant improved cellular and humoral immune responses against the transgene of interest over pVax1. The new vector, pIDV-II, offers an additional alternative for DNA based vaccination and gene therapy for animal and human use.
Collapse
Affiliation(s)
- George Giorgi Babuadze
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Jose Echanove
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Claude Lamarre
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Marc-Antoine deLaVega
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, Quebec G1V 0A6, Canada
| | - Hugues Fausther-Bovendo
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Trina Racine
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada; Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), Canada
| | - Alejandro M Gomez
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Hiva Azizi
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Mathew Wade
- Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec G1V 4G2, Canada
| | - Robert Kozak
- Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
| | - Gary P Kobinger
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Quebec City, Quebec G1V 0A6, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
| |
Collapse
|
13
|
de La Vega MA, Wong G, Wei H, He S, Bello A, Fausther-Bovendo H, Audet J, Tierney K, Tran K, Soule G, Racine T, Strong JE, Qiu X, Kobinger GP. Role of key infectivity parameters in the transmission of Ebola virus Makona in macaques. J Infect Dis 2021; 226:616-624. [PMID: 34626109 PMCID: PMC9441207 DOI: 10.1093/infdis/jiab478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 09/22/2021] [Indexed: 11/14/2022] Open
Abstract
Many characteristics associated with Ebola virus disease remain to be fully understood. It is known that direct contact with infected bodily fluids is an associated risk factor, but few studies have investigated parameters associated with transmission between individuals, such as the dose of virus required to facilitate spread and route of infection. Therefore, we sought to characterize the impact by route of infection, viremia, and viral shedding through various mucosae, with regards to intraspecies transmission of Ebola virus in a nonhuman primate model. Here, challenge via the esophagus or aerosol to the face did not result in clinical disease, although seroconversion of both challenged and contact animals was observed in the latter. Subsequent intramuscular or intratracheal challenges suggest that viral loads determine transmission likelihood to naive animals in an intramuscular-challenge model, which is greatly facilitated in an intratracheal-challenge model where transmission from challenged to direct contact animal was observed consistently.
Collapse
Affiliation(s)
- Marc Antoine de La Vega
- Département de microbiologie-infectiologie et d’immunologie, Université Laval, Québec, Québec, Canada
| | - Gary Wong
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Haiyan Wei
- Institute of Infectious Disease, Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Shihua He
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Alexander Bello
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Hugues Fausther-Bovendo
- Département de microbiologie-infectiologie et d’immunologie, Université Laval, Québec, Québec, Canada
| | - Jonathan Audet
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Kevin Tierney
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Kaylie Tran
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Geoff Soule
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Trina Racine
- Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - James E Strong
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Xiangguo Qiu
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba,Canada
| | - Gary P Kobinger
- Correspondence: Gary P. Kobinger, PhD, Département de microbiologie-infectiologie et d’immunologie, Faculté de médecine, Université Laval, 2325 Rue de l’Université, Québec, QC G1V 0A6, Canada ()
| |
Collapse
|
14
|
Wade M, Fausther-Bovendo H, De La Vega MA, Kobinger G. In vivo generation of collagen specific Tregs with AAV8 suppresses autoimmune responses and arthritis in DBA1 mice through IL10 production. Sci Rep 2021; 11:18204. [PMID: 34521922 PMCID: PMC8440515 DOI: 10.1038/s41598-021-97739-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 08/12/2021] [Indexed: 11/25/2022] Open
Abstract
Available therapeutics for autoimmune disorders focused on mitigating symptoms, rather than treating the cause of the disorder. A novel approach using adeno-associated virus (AAV) could restore tolerance to the autoimmune targets and provide a permanent treatment for autoimmune diseases. Here, we evaluated the ability of collagen II T-cell epitopes packaged in adeno-associated virus serotype 8 (AAV-8) vectors to reduce pathogenic cellular and humoral responses against collagen and to mitigate the disease in the collagen-induced arthritis mouse model. The cytokines and immune cells involved in the immune suppression were also investigated. Mice treated with AAV-8 containing collagen II T-cell epitopes demonstrated a significant reduction in the arthritis symptoms, pathogenic collagen specific antibody and T cell responses. The AAV-8 mediated immune suppression was mediated by increased interleukin-10 expression and regulatory T cells expansion. Altogether, this study strengthens the notion that AAV vectors are promising candidates for the treatment of autoimmune diseases.
Collapse
Affiliation(s)
- Matthew Wade
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Hugues Fausther-Bovendo
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Marc-Antoine De La Vega
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada
| | - Gary Kobinger
- Department of Microbiology and Immunology, Faculty of Medicine, Laval University, Quebec, Canada. .,Department of Pathology and Laboratory Medicine, University of Pennsylvania School 27 of Medicine, Philadelphia, PA, USA.
| |
Collapse
|
15
|
Rghei AD, van Lieshout LP, McLeod BM, Pei Y, Lopes JA, Zielinska N, Baracuhy EM, Stevens BAY, Thomas SP, Yates JGE, Warner BM, Kobasa D, Fausther-Bovendo H, Kobinger GP, Karimi K, Thompson B, Bridle BW, Susta L, Wootton SK. Safety and Tolerability of the Adeno-Associated Virus Vector, AAV6.2FF, Expressing a Monoclonal Antibody in Murine and Ovine Animal Models. Biomedicines 2021; 9:biomedicines9091186. [PMID: 34572372 PMCID: PMC8464737 DOI: 10.3390/biomedicines9091186] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 12/18/2022] Open
Abstract
Adeno-associated virus (AAV) vector mediated expression of therapeutic monoclonal antibodies is an alternative strategy to traditional vaccination to generate immunity in immunosuppressed or immunosenescent individuals. In this study, we vectorized a human monoclonal antibody (31C2) directed against the spike protein of SARS-CoV-2 and determined the safety profile of this AAV vector in mice and sheep as a large animal model. In both studies, plasma biochemical parameters and hematology were comparable to untreated controls. Except for mild myositis at the site of injection, none of the major organs revealed any signs of toxicity. AAV-mediated human IgG expression increased steadily throughout the 28-day study in sheep, resulting in peak concentrations of 21.4–46.7 µg/ mL, demonstrating practical scale up from rodent to large animal models. This alternative approach to immunity is worth further exploration after this demonstration of safety, tolerability, and scalability in a large animal model.
Collapse
Affiliation(s)
- Amira D. Rghei
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Laura P. van Lieshout
- Avamab Pharma Inc., 120, 4838 Richard Road SW, Calgary, AB T3E 6L1, Canada; (L.P.v.L.); (B.T.)
| | - Benjamin M. McLeod
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Yanlong Pei
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Jordyn A. Lopes
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Nicole Zielinska
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Enzo M. Baracuhy
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Brenna A. Y. Stevens
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Sylvia P. Thomas
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Jacob G. E. Yates
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Bryce M. Warner
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; (B.M.W.); (D.K.)
| | - Darwyn Kobasa
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; (B.M.W.); (D.K.)
| | - Hugues Fausther-Bovendo
- Département de Microbiologie-Infectiologie et D’immunologie, Université Laval, Quebec City, QC G1V 0A6, Canada; (H.F.-B.); (G.P.K.)
| | - Gary P. Kobinger
- Département de Microbiologie-Infectiologie et D’immunologie, Université Laval, Quebec City, QC G1V 0A6, Canada; (H.F.-B.); (G.P.K.)
| | - Khalil Karimi
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Brad Thompson
- Avamab Pharma Inc., 120, 4838 Richard Road SW, Calgary, AB T3E 6L1, Canada; (L.P.v.L.); (B.T.)
| | - Byram W. Bridle
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Leonardo Susta
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
| | - Sarah K. Wootton
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada; (A.D.R.); (B.M.M.); (Y.P.); (J.A.L.); (N.Z.); (E.M.B.); (B.A.Y.S.); (S.P.T.); (J.G.E.Y.); (K.K.); (B.W.B.); (L.S.)
- Correspondence: ; Tel.: +1-519-824-4120 (ext. 54729)
| |
Collapse
|
16
|
Affiliation(s)
| | - Gary Kobinger
- Faculty of Medicine, Université Laval, Quebec, QC, Canada. .,Galveston National Laboratory, Galveston, TX, USA
| |
Collapse
|
17
|
Loubaki L, Gantner P, Pagliuzza A, Fausther-Bovendo H, Kobinger G, Chomont N, Germain M. Testing for the presence of SARS-CoV-2 RNA in presymptomatic blood donors. Transfusion 2021; 61:649-651. [PMID: 33616976 PMCID: PMC8014243 DOI: 10.1111/trf.16155] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/03/2020] [Accepted: 10/04/2020] [Indexed: 12/26/2022]
Affiliation(s)
- Lionel Loubaki
- Héma-Québec, Affaires médicales et Innovation, Québec, Québec, Canada.,Department of Biochemistry, Microbiology and Bioinformatics, Laval University, Québec, Québec, Canada
| | - Pierre Gantner
- Centre de recherche du CHUM, Axe Immunopathologie, Montréal, Québec, Canada
| | - Amélie Pagliuzza
- Centre de recherche du CHUM, Axe Immunopathologie, Montréal, Québec, Canada
| | - Hugues Fausther-Bovendo
- Centre de recherche du CHU de Québec-Université Laval, Axe maladies infectieuses et immunitaires, Québec, Québec, Canada
| | - Gary Kobinger
- Centre de recherche du CHU de Québec-Université Laval, Axe maladies infectieuses et immunitaires, Québec, Québec, Canada
| | - Nicolas Chomont
- Centre de recherche du CHUM, Axe Immunopathologie, Montréal, Québec, Canada
| | - Marc Germain
- Héma-Québec, Affaires médicales et Innovation, Québec, Québec, Canada
| |
Collapse
|
18
|
Mhamdi Z, Fausther-Bovendo H, Uyar O, Carbonneau J, Venable MC, Abed Y, Kobinger G, Boivin G, Baz M. Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. Microorganisms 2020; 8:microorganisms8121968. [PMID: 33322333 PMCID: PMC7764069 DOI: 10.3390/microorganisms8121968] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 12/05/2020] [Accepted: 12/07/2020] [Indexed: 12/11/2022] Open
Abstract
The prolonged treatment of immunosuppressed (IS) individuals with anti-influenza monotherapies may lead to the emergence of drug-resistant variants. Herein, we evaluated oseltamivir and polymerase inhibitors combinations against influenza A/H3N2 infections in an IS mouse model. Mice were IS with cyclophosphamide and infected with 3 × 103 PFU of a mouse-adapted A/Switzerland/9715293/2013 (H3N2) virus. Forty-eight hours post-infection, the animals started oseltamivir, favipiravir or baloxavir marboxil (BXM) as single or combined therapies for 10 days. Weight losses, survival rates and lung viral titers (LVTs) were determined. The neuraminidase (NA) and polymerase genes from lung viral samples were sequenced. All untreated animals died. Oseltamivir and favipiravir monotherapies only delayed mortality (the mean day to death (MDD) of 21.4 and 24 compared to 11.4 days for those untreated) while a synergistic improvement in survival (80%) and LVT reduction was observed in the oseltamivir/favipiravir group compared to the oseltamivir group. BXM alone or in double/triple combination provided a complete protection and significantly reduced LVTs. Oseltamivir and BXM monotherapies induced the E119V (NA) and I38T (PA) substitutions, respectively, while no resistance mutation was detected with combinations. We found that the multiple dose regimen of BXM alone provided superior benefits compared to oseltamivir and favipiravir monotherapies. Moreover, we suggest the potential for drug combinations to reduce the incidence of resistance.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Mariana Baz
- Correspondence: ; Tel.: +1-(418)-525-4444 (ext. 48281)
| |
Collapse
|
19
|
Fausther-Bovendo H, Kobinger G. Vaccine innovation spurred by the long wait for an Ebola virus vaccine. Lancet Infect Dis 2020; 21:440-441. [PMID: 33217364 DOI: 10.1016/s1473-3099(20)30515-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 06/08/2020] [Indexed: 01/29/2023]
Affiliation(s)
- Hugues Fausther-Bovendo
- Centre de Recherche en Infectiologie de l'Université Laval, Université Laval, Québec City, QC G1V 4G2, Canada
| | - Gary Kobinger
- Centre de Recherche en Infectiologie de l'Université Laval, Université Laval, Québec City, QC G1V 4G2, Canada.
| |
Collapse
|
20
|
Kapetshi J, Fausther-Bovendo H, Corbett C, Leung A, Ait-Ikhlef K, Nsio J, Aruna A, Kebela Ilunga B, Muyembe JJ, Formenty P, Kobinger GP. Contribution of Environment Sample-Based Detection to Ebola Outbreak Management. J Infect Dis 2019; 218:S292-S296. [PMID: 30325435 DOI: 10.1093/infdis/jiy366] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Detection of chains of transmission is critical to interrupt Ebola virus (EBOV) outbreaks. For >25 years, quantitative reverse transcription polymerase chain reaction performed on biological fluids has been the reference standard for EBOV detection and identification. In the current study, we investigated the use of environmental sampling to detect EBOV shed from probable case patients buried without the collection of bodily fluids. During the 2012 Bundibugyo virus (BDBV) outbreak in the Democratic Republic of the Congo, environmental samples were screened for BDBV RNA by means of real-time polymerase chain reaction. Low levels of BDBV genomic RNA were detected in a hospital and in a house. Detection of BDBV RNA in the house led to the identification of the last chain of transmission still active, which resulted in the safe burial of the person with the last laboratory-confirmed case of this outbreak. Overall, environmental sampling can fill specific gaps to help confirm EBOV positivity and therefore be of value in outbreak management.
Collapse
Affiliation(s)
- Jimmy Kapetshi
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.,University of Kinshasa, Kinshasa, Democratic Republic of the Congo
| | | | | | - Anders Leung
- Public Health Agency of Canada, Winnipeg, Manitoba
| | - Kamal Ait-Ikhlef
- World Health Organization, Emerging and Dangerous Pathogens Laboratory Network, Geneva, Switzerland
| | - Justus Nsio
- Heath Ministry, Kinshasa, Democratic Republic of the Congo
| | - Aaron Aruna
- Heath Ministry, Kinshasa, Democratic Republic of the Congo
| | | | - Jean-Jacques Muyembe
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.,University of Kinshasa, Kinshasa, Democratic Republic of the Congo
| | | | - Gary P Kobinger
- Laval University, Quebec, Quebec.,University of Pennsylvania School, Philadelphia
| |
Collapse
|
21
|
Nsio J, Kapetshi J, Makiala S, Raymond F, Tshapenda G, Boucher N, Corbeil J, Okitandjate A, Mbuyi G, Kiyele M, Mondonge V, Kikoo MJ, Van Herp M, Barboza P, Petrucci R, Benedetti G, Formenty P, Muyembe Muzinga B, Ilunga Kalenga O, Ahuka S, Fausther-Bovendo H, Ilunga BK, Kobinger GP, Muyembe JJT. 2017 Outbreak of Ebola Virus Disease in Northern Democratic Republic of Congo. J Infect Dis 2019; 221:701-706. [DOI: 10.1093/infdis/jiz107] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 03/22/2019] [Indexed: 11/12/2022] Open
Affiliation(s)
- Justus Nsio
- Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Jimmy Kapetshi
- Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
| | - Sheila Makiala
- Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
| | | | | | | | | | | | - Gisele Mbuyi
- Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Musa Kiyele
- Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Vital Mondonge
- World Health Organization (WHO), Kinshasa, Democratic Republic of the Congo
| | - Marie Jose Kikoo
- World Health Organization (WHO), Kinshasa, Democratic Republic of the Congo
| | | | | | | | - Guido Benedetti
- Medical Department, Operational Centre–Brussels, MSF, Luxembourg, Luxembourg
| | | | - Baby Muyembe Muzinga
- Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
| | | | - Steve Ahuka
- Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
| | | | | | | | | |
Collapse
|
22
|
Fausther-Bovendo H, Qiu X, McCorrister S, Westmacott G, Sandstrom P, Castilletti C, Di Caro A, Ippolito G, Kobinger GP. Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep 2017; 7:42147. [PMID: 28181533 PMCID: PMC5299614 DOI: 10.1038/srep42147] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 01/05/2017] [Indexed: 11/15/2022] Open
Abstract
Ebola virus (EBOV) survivors are affected by a variety of serious illnesses of unknown origin for years after viral clearance from the circulation. Identifying the causes of these persistent illnesses is paramount to develop appropriate therapeutic protocols. In this study, using mouse and non-human primates which survived EBOV challenge, ELISA, western blot, mass spectrometry and flow cytometry were used to screen for autoantibodies, identify their main targets, investigate the mechanism behind their induction and monitor autoantibodies accumulation in various tissues. In infected mice and NHP, polyclonal B cell activation and autoantigens secretion induced autoantibodies against dsDNA and heat shock protein 60 as well as antibody accumulation in tissues associated with long-term clinical manifestations in humans. Finally, the presence of these autoantibodies was confirmed in human EBOV survivors. Overall, this study supports the concept that autoimmunity is a causative parameter that contributes to the various illnesses observed in EBOV survivors.
Collapse
Affiliation(s)
- H Fausther-Bovendo
- University of Manitoba, Winnipeg, Canada.,National Microbiology Laboratory, Public health Agency of Canada, Winnipeg, Canada
| | - X Qiu
- University of Manitoba, Winnipeg, Canada.,National Microbiology Laboratory, Public health Agency of Canada, Winnipeg, Canada
| | - S McCorrister
- JC Wilt Infectious Disease Research Centre, Winnipeg, Canada
| | - G Westmacott
- JC Wilt Infectious Disease Research Centre, Winnipeg, Canada
| | - P Sandstrom
- JC Wilt Infectious Disease Research Centre, Winnipeg, Canada.,National HIV and Retrovirology Laboratory, Ottawa, Canada
| | - C Castilletti
- Lazzaro Spallanzani, National Institute for Infectious Diseases-IRCCS, Rome, Italy
| | - A Di Caro
- Lazzaro Spallanzani, National Institute for Infectious Diseases-IRCCS, Rome, Italy
| | - G Ippolito
- Lazzaro Spallanzani, National Institute for Infectious Diseases-IRCCS, Rome, Italy
| | - G P Kobinger
- National Microbiology Laboratory, Public health Agency of Canada, Winnipeg, Canada.,Department of Pathology and Laboratory Medicine, University of Pennsylvania School 27 of Medicine, Philadelphia, PA, USA.,Laval University, Department of Microbiology and Immunology, Faculty of Medicine, Quebec, Canada
| |
Collapse
|
23
|
Wong G, Qiu X, de La Vega MA, Fernando L, Wei H, Bello A, Fausther-Bovendo H, Audet J, Kroeker A, Kozak R, Tran K, He S, Tierney K, Soule G, Moffat E, Günther S, Gao GF, Strong J, Embury-Hyatt C, Kobinger G. Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. J Infect Dis 2016; 214:S281-S289. [PMID: 27651412 DOI: 10.1093/infdis/jiw267] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Enhanced virulence and/or transmission of West African Ebola virus (EBOV) variants, which are divergent from their Central African counterparts, are suspected to have contributed to the sizable toll of the recent Ebola virus disease (EVD) outbreak. This study evaluated the pathogenicity and shedding in rhesus macaques infected with 1 of 2 West African isolates (EBOV-C05 or EBOV-C07) or a Central African isolate (EBOV-K). All animals infected with EBOV-C05 or EBOV-C07 died of EVD, whereas 2 of 3 EBOV-K-infected animals died. The viremia level was elevated 10-fold in EBOV-C05-infected animals, compared with EBOV-C07- or EBOV-K-infected animals. More-severe lung pathology was observed in 2 of 6 EBOV-C05/C07-infected macaques. This is the first detailed analysis of the recently circulating EBOV-C05/C07 in direct comparison to EBOV-K with 6 animals per group, and it showed that EBOV-C05 but not EBOV-C07 can replicate at higher levels and cause more tissue damage in some animals. Increased virus shedding from individuals who are especially susceptible to EBOV replication is possibly one of the many challenges facing the community of healthcare and policy-making responders since the beginning of the outbreak.
Collapse
Affiliation(s)
- Gary Wong
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing
| | - Xiangguo Qiu
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology
| | - Marc-Antoine de La Vega
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Immunology, University of Manitoba
| | - Lisa Fernando
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Haiyan Wei
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Alexander Bello
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology
| | | | - Jonathan Audet
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology
| | - Andrea Kroeker
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Robert Kozak
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Kaylie Tran
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Shihua He
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Kevin Tierney
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Geoff Soule
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Estella Moffat
- National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, Canada
| | - Stephan Günther
- Bernhard-Nocht-Institute for Tropical Medicine, World Health Organization Collaborating Center for Arboviruses and Hemorrhagic Fever Reference and Research, Hamburg, Germany
| | - George F Gao
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing
| | - Jim Strong
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
| | - Carissa Embury-Hyatt
- National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, Canada
| | - Gary Kobinger
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology Department of Immunology, University of Manitoba Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
| |
Collapse
|
24
|
Abstract
Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the human population is widespread, thus hampering its clinical use. Various components of the immune system, including neutralizing antibodies (nAbs), Ad specific T cells and type I IFN activated NK cells, contribute to dampening the efficacy of Ad vectors in individuals with pre-existing Ad immunity. In order to circumvent pre-existing immunity to adenovirus, numerous strategies, such as developing alternative Ad serotypes, varying immunization routes and utilizing prime-boost regimens, are under pre-clinical or clinical phases of development. However, these strategies mainly focus on one arm of pre-existing immunity. Selection of alternative serotypes has been largely driven by the absence in the human population of nAbs against them with little attention paid to cross-reactive Ad specific T cells. Conversely, varying the route of immunization appears to mainly rely on avoiding Ad specific tissue-resident T cells. Finally, prime-boost regimens do not actually circumvent pre-existing immunity but instead generate immune responses of sufficient magnitude to confer protection despite pre-existing immunity. Combining the above strategies and thus taking into account all components regulating pre-existing Ad immunity will help further improve the development of Ad vectors for animal and human use.
Collapse
|
25
|
Aviles J, Bello A, Wong G, Fausther-Bovendo H, Qiu X, Kobinger G. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. J Infect Dis 2015; 212 Suppl 2:S389-97. [DOI: 10.1093/infdis/jiv175] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53. [PMID: 25171469 PMCID: PMC4214273 DOI: 10.1038/nature13777] [Citation(s) in RCA: 700] [Impact Index Per Article: 70.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/21/2014] [Indexed: 12/29/2022]
Abstract
Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use.
Collapse
Affiliation(s)
- Xiangguo Qiu
- National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
| | - Gary Wong
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Jonathan Audet
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Alexander Bello
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Lisa Fernando
- National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
| | - Judie B Alimonti
- National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
| | - Hugues Fausther-Bovendo
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Haiyan Wei
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Institute of Infectious Disease, Henan Centre for Disease Control and Prevention, Zhengzhou, 450012 Henan, China
| | - Jenna Aviles
- National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
| | - Ernie Hiatt
- Kentucky BioProcessing, Owensboro, Kentucky 42301, USA
| | | | - Josh Morton
- Kentucky BioProcessing, Owensboro, Kentucky 42301, USA
| | - Kelsi Swope
- Kentucky BioProcessing, Owensboro, Kentucky 42301, USA
| | - Ognian Bohorov
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | | | - Charles Goodman
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | - Do Kim
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | - Michael H Pauly
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | - Jesus Velasco
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | - James Pettitt
- 1] United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland 21702, USA [2] Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland 21702, USA
| | - Gene G Olinger
- 1] United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland 21702, USA [2] Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland 21702, USA
| | - Kevin Whaley
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | - Bianli Xu
- Institute of Infectious Disease, Henan Centre for Disease Control and Prevention, Zhengzhou, 450012 Henan, China
| | - James E Strong
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada [3] Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba R3A 1S1, Canada
| | - Larry Zeitlin
- Mapp Biopharmaceutical Inc., San Diego, California 92121, USA
| | - Gary P Kobinger
- 1] National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada [3] Department of Immunology, University of Manitoba, Winnipeg, Manitoba R3E 0T5, Canada [4] Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
| |
Collapse
|
27
|
Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, Qiu X. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014; 32:5722-9. [PMID: 25173474 PMCID: PMC7115511 DOI: 10.1016/j.vaccine.2014.08.028] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Revised: 08/09/2014] [Accepted: 08/15/2014] [Indexed: 01/16/2023]
Abstract
VSV-based vaccine protects guinea pigs from Ebola at 18 months post-immunization. Glycoprotein-specific IgG antibody responses are indicative of induced protection. Results support further long-term protection studies in nonhuman primates.
Ebola virus (EBOV) infections cause lethal hemorrhagic fever in humans, resulting in up to 90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a vaccine that is able to provide durable immunity is needed to protect those who are at risk of exposure to the virus. This study assesses the long-term efficacy of the vesicular stomatitis virus (VSV)-based vaccine (VSVΔG/EBOVGP) in two rodent models of EBOV infection. Mice and guinea pigs were first immunized with 2 × 104 or 2 × 105 plaque forming units (PFU) of VSVΔG/EBOVGP, respectively. Challenge of mice with a lethal dose of mouse-adapted EBOV (MA-EBOV) at 6.5 and 9 months after vaccination provided complete protection, and 80% (12 of 15 survivors) protection at 12 months after vaccination. Challenge of guinea pigs with a lethal dose of guinea pig-adapted EBOV (GA-EBOV) at 7, 12 and 18 months after vaccination resulted in 83% (5 of 6 survivors) at 7 months after vaccination, and 100% survival at 12 and 18 months after vaccination. No weight loss or clinical signs were observed in the surviving animals. Antibody responses were analyzed using sera from individual rodents. Levels of EBOV glycoprotein-specific IgG antibody measured immediately before challenge appeared to correlate with protection. These studies confirm that vaccination with VSVΔG/EBOVGP is able to confer long-term protection against Ebola infection in mice and guinea pigs, and support follow-up studies in non-human primates.
Collapse
Affiliation(s)
- Gary Wong
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
| | - Jonathan Audet
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
| | - Lisa Fernando
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada
| | - Hugues Fausther-Bovendo
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada
| | - Judie B Alimonti
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada
| | - Gary P Kobinger
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada; Department of Immunology, University of Manitoba, Winnipeg, MB, Canada; Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
| | - Xiangguo Qiu
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada.
| |
Collapse
|
28
|
Sullivan NJ, Fausther-Bovendo H, Nabel GJ. Ebola vaccine. Vaccines (Basel) 2013. [DOI: 10.1016/b978-1-4557-0090-5.00049-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
29
|
Liang F, Sandgren KJ, Fausther-Bovendo H, O'hagan D, Seubert A, De Gregorio E, Rao S, Sullivan N, Seder RA, Koup RA, Loré K. Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant. Retrovirology 2012. [PMCID: PMC3441738 DOI: 10.1186/1742-4690-9-s2-o16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Fausther-Bovendo H, Mulangu S, Sullivan NJ. Ebolavirus vaccines for humans and apes. Curr Opin Virol 2012; 2:324-9. [PMID: 22560007 DOI: 10.1016/j.coviro.2012.04.003] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Revised: 04/10/2012] [Accepted: 04/11/2012] [Indexed: 11/25/2022]
Abstract
Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.
Collapse
|
31
|
Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debré P. HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog 2010; 6:e1000975. [PMID: 20617170 PMCID: PMC2895652 DOI: 10.1371/journal.ppat.1000975] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2009] [Accepted: 05/28/2010] [Indexed: 12/21/2022] Open
Abstract
CD4+ T cell loss is central to HIV pathogenesis. In the initial weeks post-infection, the great majority of dying cells are uninfected CD4+ T cells. We previously showed that the 3S motif of HIV-1 gp41 induces surface expression of NKp44L, a cellular ligand for an activating NK receptor, on uninfected bystander CD4+ T cells, rendering them susceptible to autologous NK killing. However, the mechanism of the 3S mediated NKp44L surface expression on CD4+ T cells remains unknown. Here, using immunoprecipitation, ELISA and blocking antibodies, we demonstrate that the 3S motif of HIV-1 gp41 binds to gC1qR on CD4+ T cells. We also show that the 3S peptide and two endogenous gC1qR ligands, C1q and HK, each trigger the translocation of pre-existing NKp44L molecules through a signaling cascade that involves sequential activation of PI3K, NADPH oxidase and p190 RhoGAP, and TC10 inactivation. The involvement of PI3K and NADPH oxidase derives from 2D PAGE experiments and the use of PIP3 and H2O2 as well as small molecule inhibitors to respectively induce and inhibit NKp44L surface expression. Using plasmid encoding wild type or mutated form of p190 RhoGAP, we show that 3S mediated NKp44L surface expression on CD4+ T cells is dependent on p190 RhoGAP. Finally, the role of TC10 in NKp44L surface induction was demonstrated by measuring Rho protein activity following 3S stimulation and using RNA interference. Thus, our results identify gC1qR as a new receptor of HIV-gp41 and demonstrate the signaling cascade it triggers. These findings identify potential mechanisms that new therapeutic strategies could use to prevent the CD4+ T cell depletion during HIV infection and provide further evidence of a detrimental role played by NK cells in CD4+ T cell depletion during HIV-1 infection. HIV infected individuals suffer from a loss of CD4+ lymphocytes. Initially, dying CD4+ lymphocytes are mainly infected ones. Afterward, the great majority of dying CD4+ lymphocytes are uninfected. The cause of uninfected CD4+ lymphocyte death during HIV infection is still under debate. We previously showed that one of the HIV-1 envelop proteins, gp41, induces the expression of a stress molecule called NKp44L on the surface of uninfected CD4+ lymphocytes. Uninfected CD4+ lymphocytes expressing NKp44L are killed, in vitro and in vivo, by cells of the immune system called NK cells. In this report, we study the CD4+ lymphocyte's proteins involved in the expression of NKp44L. To do so, we used several techniques to identify interacting or differentially expressed proteins and to inhibit or monitor enzymes activity. We also induce NKp44L using the product of some of the proteins involved in NKp44L expression. We found that HIV-1 gp41 binds to its receptor gC1qR on CD4+ lymphocytes. This interaction respectively activates the PI3K, the NADPH oxidase and p190 RhoGAP which inactivates TC10. Using the obtained data we build a model of the protein cascade involved in NKp44L surface expression.
Collapse
Affiliation(s)
- Hugues Fausther-Bovendo
- Laboratoire Immunité et Infection, Institut National de la Santé et de la Recherche Médicale UMR-S 945 I, Paris, France
- Université Pierre et Marie Curie (Paris 6), Paris, France
| | - Vincent Vieillard
- Laboratoire Immunité et Infection, Institut National de la Santé et de la Recherche Médicale UMR-S 945 I, Paris, France
- Université Pierre et Marie Curie (Paris 6), Paris, France
| | - Sandrine Sagan
- Université Pierre et Marie Curie (Paris 6), Paris, France
- Laboratoire des Biomolécules, Centre National de la Recherche Scientifique UMR 7203, Paris, France
| | - Georges Bismuth
- Institut Cochin, Université Paris Descarte, Centre National de la Recherche Scientifique UMR 8104, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
- Institut National de la Santé et de la Recherche Médicale, U567, Paris, France
| | - Patrice Debré
- Laboratoire Immunité et Infection, Institut National de la Santé et de la Recherche Médicale UMR-S 945 I, Paris, France
- Université Pierre et Marie Curie (Paris 6), Paris, France
- * E-mail:
| |
Collapse
|
32
|
Vieillard V, Dereuddre-Bosquet N, Corneau A, Mangeot-Méderle I, Fausther-Bovendo H, Le Grand R, Debre P. Towards a vaccine against AIDS. Retrovirology 2010. [PMCID: PMC3316007 DOI: 10.1186/1742-4690-7-s1-i32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
|
33
|
Fausther-Bovendo H, Sol-Foulon N, Schwartz O, Debre P, Vieillard V. OA031-05. HIV escape from natural killer cytotoxicity: Nef inhibits NKp44L expression on HIV-infected CD4+ T cells. Retrovirology 2009. [PMCID: PMC2767544 DOI: 10.1186/1742-4690-6-s3-o23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
34
|
Vieillard V, Fausther-Bovendo H, Le Grand R, Debre P. P19-25. A vaccine model to prevent the depletion of uninfected bystander CD4 cells during HIV infection. Retrovirology 2009. [PMCID: PMC2767854 DOI: 10.1186/1742-4690-6-s3-p345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
35
|
Fausther-Bovendo H, Wauquier N, Cherfils-Vicini J, Cremer I, Debré P, Vieillard V. NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. AIDS 2008; 22:217-26. [PMID: 18097224 DOI: 10.1097/qad.0b013e3282f46e7c] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND Gammadelta T cells share with natural killer (NK) cells many effector capabilities and cell-surface proteins, including the NKG2 receptor family. A subset of gammadelta T cells that express the variable Vdelta1 region plays a critical role in immune regulation, tumour surveillance and viral infection. Dramatic expansion of Vdelta1 T cells has been observed in HIV disease. OBJECTIVE To determine if NKG2C expression on Vdelta1 T cells during HIV-1 infection is correlated with CD4 cell count and involved in lysis of CD4 T cells. METHODS gammadelta T cells from viraemic HIV-infected patients were examined. Expression of NK cell markers was analyzed by flow cytometry. The cytolytic activity of Vdelta1 T cells was determined by either Cr-release assays or degranulation assays against HLA-E-transfected 721.221 cells or HIV-infected CD4 primary T cells. RESULTS The expression of C-type lectin NKG2 receptors was sharply modulated on gammadelta T cells in patients with HIV infection. A profound decrease of Vdelta1 T cells bearing inhibitory NKG2A receptors corresponded to a drastic expansion of a distinct population of Vdelta1 T cells expressing a functional activating NKG2C receptor. Engagement of HLA-E, the ligand of both NKG2A and NKG2C, which is specifically induced on HIV-infected CD4 T cells, substantially enhanced the Vdelta1 T cell-mediated cytotoxicity. CONCLUSIONS These results raise the possibility that induction of NKG2C expression on Vdelta1 T cells plays a key role in the destruction of HIV-infected CD4 T cells during HIV disease.
Collapse
Affiliation(s)
- Hugues Fausther-Bovendo
- Institut National de la Santé et de la Recherche Scientifique U543, Université Pierre et Marie Curie Paris-6, France
| | | | | | | | | | | |
Collapse
|